AI-powered trial analysis backed by current medical evidence.
Get StartedWe search ClinicalTrials.gov for active trials matching your condition and filter them for relevance.
Each trial is checked against recent medical literature for relevance to your condition.
You get ranked trials with plain-language explanations for each recommendation.
| Without ClinTrialFinder | With ClinTrialFinder | |
|---|---|---|
| Results | Hundreds of trials to sift through | Top trials ranked by an overall suitability score |
| Context | Eligibility criteria only | Evidence summary for each trial |
| Language | Technical medical terms | Plain-language explanations |
Example search: Recurrent glioblastoma (IDH-wildtype, MGMT unmethylated), post Stupp protocol and bevacizumab/lomustine
Results: 207 trials analyzed, 108 recommended — ranked by confidence tier with evidence summaries, surfacing reasons, and risk flags
Score: 85/100 — Excellent Match · Strong Evidence
Why surfaced: Recurrent GBM eligible · Regorafenib with phase 2 evidence · Adaptive phase 2/3 platform
Evidence: Patient with progressive recurrent GBM fits trial; regorafenib arm offers modest survival benefit post-standard therapy; phase 2/3 adaptive design; manageable safety; trial recruiting.
Uses AI-based matching algorithms and current medical evidence from trusted sources.
Searches the official ClinicalTrials.gov database directly for your condition.
Developed by a data scientist with personal experience navigating clinical trials. Learn more
It searches ClinicalTrials.gov for any condition. Results quality depends on how many active trials exist for your disease.
ClinicalTrials.gov lists all trials. We rank them using AI-based eligibility scoring and evidence from recent medical literature, with plain-language explanations.
Built by a data scientist with personal experience navigating clinical trials.
Most searches complete within 2–5 minutes. You can leave the page and come back later — your results will be saved. If you provide your email, we'll notify you when results are ready.
PSMA radioligand expansion beyond Pluvicto (actinium-225 AAA817 in AcTFirst/PSMAcTION; ProstACT Global 177Lu-TLX591; PEACE6-Poor Responders). Next-gen AR-pathway (BMS-986365 post-ARPI mCRPC, opevesostat CYP11A1i, Apa/Enza-short low-volume mCSPC). Saruparib PARP in mCSPC + BRCAm localised high-risk. KLK2-comPAS pasritamig T-cell engager.
Pancreatic Cancer Trials at ASCO 2026Daraxonrasib pan-RAS(ON) Phase 3s RASolute 303 (1L metastatic) + 304 (adjuvant); IBI343 claudin 18.2 ADC; ponsegromab cachexia; PLATINUM-CAN BRCA second-line; ivonescimab + AK117. What PDAC patients should ask.
T-Cell Engagers at ASCO 2026MajesTEC-9 (teclistamab vs PVd/Kd in R/R myeloma) confirmed; tarlatamab long-term + SubQ/outpatient in ES-SCLC; CD20 lymphoma 1L combinations; solid-tumor TCE wave (CLDN18.2, MUC16, GPC3, KLK2, STEAP1).